Bristol-Myers Squibb has discontinued the development of muraglitazar, a dual alpha/gamma PPAR (peroxisome proliferator-activated receptor) agonist in development for type 2 diabetes and will focus its efforts on other priority portfolio projects. On October 18, 2005, the FDA issued an approvable letter for muraglitazar requesting additional information on the drug’s cardiovascular safety profile. Since that time, the company has continued to further its understanding of the compound....